Stock listing

NASDAQ:ONCY Oncolytics Biotech Inc. Stock

Home listing (NASDAQ) of Oncolytics Biotech Inc.

Follow Oncolytics Biotech Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ONCY

$0.35 USD -0.04 (-10.4%)

Close on Nov 20, 2026

Past year -64.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.34 – $0.389 USDNov 20, 2026
Volume
1.10M sharesNov 20, 2026
Market cap
$47.66M USDAt the close on Nov 20, 2026 · price × 136.1M shares outstanding
52-week range
$0.333 – $1.30 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$672,271 USDMedian day 858,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Oncolytics Biotech Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ONCY · Home$0.35 USD-0.04 (-10.4%)1,096,588$0.38$0.389$0.34$0.391Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ONCY · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.35-0.04-10.4%$0.38$0.389$0.341,096,588
$0.391-0.05-11.3%$0.443$0.46$0.391,697,693
$0.44+0.058+15.1%$0.39$0.445$0.3772,185,488
$0.383+0.043+12.5%$0.334$0.393$0.3331,587,161
$0.34-0.03-8.1%$0.371$0.376$0.3371,326,598
$0.370.000.0%$0.38$0.39$0.341,263,700
$0.37-0.04-9.8%$0.41$0.42$0.37817,100
$0.41+0.03+7.9%$0.40$0.42$0.371,495,800
$0.38-0.03-7.3%$0.41$0.42$0.38542,500
$0.41-0.03-6.8%$0.45$0.46$0.381,138,900
$0.44-0.01-2.2%$0.46$0.46$0.43512,400
$0.45+0.03+7.1%$0.43$0.46$0.382,857,800
$0.42+0.03+7.7%$0.41$0.44$0.39873,200
$0.39-0.01-2.5%$0.40$0.41$0.38553,700
$0.40-0.03-7.0%$0.42$0.43$0.39844,400
$0.430.000.0%$0.42$0.43$0.41764,200
$0.43-0.01-2.3%$0.44$0.45$0.43607,300
$0.44-0.02-4.3%$0.46$0.46$0.432,190,100
$0.46-0.01-2.1%$0.47$0.50$0.46859,300
$0.47-0.03-6.0%$0.51$0.52$0.47710,300
$0.500.000.0%$0.51$0.51$0.49375,800
$0.50-0.01-2.0%$0.50$0.52$0.50405,600
$0.51+0.01+2.0%$0.50$0.52$0.49771,600
$0.500.000.0%$0.51$0.52$0.491,198,100
$0.500.000.0%$0.51$0.55$0.49690,500
$0.50-0.05-9.1%$0.55$0.55$0.491,336,600
$0.55+0.01+1.9%$0.55$0.59$0.521,300,700
$0.54+0.05+10.2%$0.50$0.56$0.443,155,000
$0.49+0.02+4.3%$0.49$0.50$0.454,202,500
$0.47-0.09-16.1%$0.57$0.59$0.443,317,400
$0.56+0.02+3.7%$0.55$0.57$0.531,459,000
$0.54-0.06-10.0%$0.60$0.61$0.541,122,200
$0.600.000.0%$0.59$0.61$0.58669,000
$0.600.000.0%$0.60$0.61$0.58858,500
$0.60-0.03-4.8%$0.64$0.64$0.581,936,400
$0.63-0.01-1.6%$0.65$0.65$0.62609,300
$0.64-0.03-4.5%$0.67$0.68$0.63689,800
$0.670.000.0%$0.68$0.68$0.65867,000
$0.67+0.01+1.5%$0.67$0.68$0.66779,000
$0.66-0.02-2.9%$0.68$0.72$0.661,129,200
$0.680.000.0%$0.69$0.69$0.67822,000
$0.680.000.0%$0.68$0.69$0.641,213,700
$0.68-0.03-4.2%$0.73$0.73$0.661,890,900
$0.71-0.06-7.8%$0.76$0.78$0.712,075,200
$0.770.000.0%$0.77$0.79$0.76693,300
$0.770.000.0%$0.78$0.78$0.76491,500
$0.770.000.0%$0.78$0.80$0.77594,200
$0.77-0.01-1.3%$0.78$0.80$0.76958,300
$0.78-0.03-3.7%$0.83$0.84$0.78903,100
$0.81+0.06+8.0%$0.76$0.85$0.761,399,400
$0.75-0.02-2.6%$0.77$0.77$0.731,198,300
$0.77-0.03-3.8%$0.79$0.83$0.763,787,600
$0.80-0.01-1.2%$0.80$0.83$0.79741,300
$0.81-0.03-3.6%$0.83$0.84$0.791,140,800
$0.84-0.02-2.3%$0.84$0.85$0.83463,700
$0.86-0.02-2.3%$0.88$0.89$0.84582,800
$0.88+0.04+4.8%$0.85$0.91$0.841,585,400
$0.840.000.0%$0.83$0.86$0.83435,100
$0.84-0.02-2.3%$0.85$0.87$0.83428,900
$0.86+0.01+1.2%$0.84$0.86$0.82673,100
$0.85-0.01-1.2%$0.86$0.87$0.84569,100
$0.860.000.0%$0.86$0.87$0.84410,100
$0.86+0.02+2.4%$0.85$0.87$0.84775,300
$0.840.000.0%$0.85$0.85$0.80486,400
$0.84+0.04+5.0%$0.80$0.85$0.80539,900
$0.80-0.03-3.6%$0.83$0.83$0.79682,000

Splits

1 split · NASDAQ:ONCY · every price before a split is adjusted for it

DayRatioWhat
2-for-19Consolidation
Ticker
NASDAQ:ONCY
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Oncolytics Biotech Inc. news

Oncolytics Biotech Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
37 in the last 12 months · 310 in all · newest Nov 13, 2026 · oldest 2016
Calls
16 calls with a replay · 16 with a transcript · latest Aug 7, 2025
Decks
30 decks · latest August 2026

Where Oncolytics Biotech Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ONCY · Home listing · This pageNASDAQUnited StatesUSD
BOATS:ONCYBOATSUnited StatesUSD

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$45.23M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
1.27

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Oncolytics Biotech Inc. · NASDAQ:ONCYUS$47.66MUS$45.23Mn/an/an/an/an/an/a1.27
Acrivon Therapeutics, Inc. · NASDAQ:ACRVUS$49.35M−US$26.60Mn/an/an/a0.7×n/a0.0×2.09
SYNTHAVERSE Spolka Akcyjna · GPW:SVEUS$48.68MUS$70.98Mn/a5.9×n/a1.7×−43.1%0.8×n/a
Heron Therapeutics, Inc. · NASDAQ:HRTXUS$48.04MUS$156.3Mn/a1.1×n/a9.8×−14.5%26.8×1.93
Helix BioPharma Corp. · TSX:HBPUS$47.94MUS$50.27Mn/an/an/a4.8×n/a0.3×0.36
THX Pharma · EURONEXT:ALTHXUS$47.23MUS$30.92Mn/an/an/a14.5×n/a0.9×n/a
FluoGuide A/S · OMXSTO:FLUOUS$47.17MUS$43.89Mn/a5,538×n/a10.5×n/a0.9×n/a
Rafael Holdings, Inc. · NYSE:RFLUS$47.10MUS$25.00Mn/a28.6×n/a0.7×n/a0.0×0.92
Bio-fd&c Co. Ltd · KRX:251120US$46.73MUS$5.29M9.8×0.4×0.9×0.9×32.8%0.0×n/a
Andros Pharmaceuticals Co., Ltd. · TPEX:6917US$46.01MUS$35.88Mn/a213×n/a3.1×−969.3%0.0×n/a
Werewolf Therapeutics, Inc. · NASDAQ:HOWLUS$46.01MUS$4.14Mn/an/an/a6.8×n/a0.0×1.55
Median of the othersUS$47.20MUS$33.40M9.8×17.3×0.9×4.0×−28.8%0.2×1.55

Forecasts

2 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 13, 2026. Not 6ix's view and not investment advice.

Price target
4.42 USD · Analysts' mean
EPS, year to Dec 2026
-0.38 · 2 analysts

Team and board

Officers

OfficerRole
Jared KellyChief Executive Officer & Director
Kirk LookChief Financial Officer
John McAdoryChief Operating Officer
Jon PattonDirector of Investor Relations & Communication
Allison HagermanChief Technology Officer
Andrew AromandoChief Business Officer
Thomas C. HeinemanChief Medical Officer

Board

DirectorRole
Wayne PisanoChair
Angela HolthamDirector
Bernd R. SeizingerDirector
Deborah M. BrownDirector
James T. ParsonsDirector
Jared KellyChief Executive Officer & Director
Jonathan RigbyDirector
Pat AndrewsDirector
Steve GloverDirector

Events

Calls

CallWhenStatus
Oncolytics Biotech (NASDAQ:ONCY) Q2 2025 Earnings CallThu, Aug 07, 2025 · 4:30 PM ETReplay
Oncolytics Biotech (NASDAQ:ONCY) Q1 2025 Earnings CallWed, May 14, 2025 · 4:30 PM ETReplay
Oncolytics Biotech (NASDAQ:ONCY) Q4 2024 Earnings CallFri, Mar 07, 2025 · 8:30 AM ETReplay
Oncolytics Biotech (NASDAQ:ONCY) Q3 2024 Earnings CallTue, Nov 12, 2024 · 8:30 AM ETReplay
Oncolytics Biotech (NASDAQ:ONCY) Q2 2024 Earnings CallThu, Aug 01, 2024 · 4:30 PM ETReplay
Oncolytics Biotech (NASDAQ:ONCY) Q1 2024 Earnings CallThu, May 09, 2024 · 4:30 PM ETReplay
Oncolytics Biotech (NASDAQ:ONCY) Q4 2023 Earnings CallThu, Mar 07, 2024 · 4:30 PM ETReplay
Oncolytics Biotech (NASDAQ:ONCY) Q3 2023 Earnings CallFri, Nov 03, 2023 · 8:30 AM ETReplay
Oncolytics Biotech (NASDAQ:ONCY) Q2 2023 Earnings CallThu, Aug 10, 2023 · 12:00 PM ETReplay
Oncolytics Biotech (NASDAQ:ONCY) Q1 2023 Earnings CallFri, May 05, 2023 · 8:30 AM ETReplay
All 16 calls
CallWhenStatus
Oncolytics Biotech (NASDAQ:ONCY) Q4 2022 Earnings CallFri, Mar 03, 2023 · 8:30 AM ETReplay
Oncolytics Biotech (NASDAQ:ONCY) Q3 2022 Earnings CallMon, Nov 07, 2022 · 8:30 AM ETReplay
Oncolytics Biotech (NASDAQ:ONCY) Q2 2022 Earnings CallThu, Aug 11, 2022 · 8:30 AM ETReplay
Oncolytics Biotech (NASDAQ:ONCY) Q1 2022 Earnings CallThu, May 05, 2022 · 5:00 PM ETReplay
Oncolytics Biotech (NASDAQ:ONCY) Q4 2021 Earnings CallThu, Mar 03, 2022 · 5:00 PM ETReplay
Oncolytics Biotech (NASDAQ:ONCY) Q3 2021 Earnings CallFri, Nov 05, 2021 · 8:00 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 13, 2026 · After close−8.1%
Q2 2026Aug 12, 2026 · After close−2.4%
Q1 2026May 14, 2026 · After close−2.3%
Q4 2025Mar 5, 20260.0%
Q3 2025Nov 12, 2025 · After close−4.8%
Q2 2025Aug 8, 2025 · Before open−6.2%
Q1 2025May 7, 2025 · Before open+1.6%
Q4 2024Mar 7, 2025 · Before open−6.3%
Q3 2024Nov 12, 2024 · Before open+3.7%
Q2 2024Aug 1, 2024 · After close−1.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · After close−5.7%
Q4 2023Mar 7, 2024 · After close+1.0%
Q3 2023Nov 3, 2023 · Before open−3.9%
Q2 2023Aug 14, 2023 · Before open+1.0%
Q1 2023May 5, 2023 · Before open+10.3%
Q4 2022Mar 3, 2023 · Before open−5.4%
Q3 2022Nov 7, 2022 · Before open+19.1%
Q2 2022Aug 11, 2022 · Before open+0.0%
Q1 2022May 5, 2022 · After close0.0%
Q4 2021Mar 2, 2022 · After close−5.8%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (August 2026)Investor deck27 slidesAugust 2026
Investor Presentation (June 2026)Investor deck27 slidesJune 2026
Investor Presentation (April 2026)Investor deck26 slidesApril 2026
Investor Presentation (March 2026)Investor deck23 slidesMarch 2026
Investor Presentation (February 2026)Investor deck23 slidesFebruary 2026
Investor Presentation (October 2025)Investor deck21 slidesOctober 2025
Investor Presentation (March 2025)Investor deck42 slidesMarch 2025
Investor Presentation (December 2024)Investor deck43 slidesDecember 2024
Investor Presentation (October 2024)Investor deck41 slidesOctober 2024
Investor Presentation (October 2024)Investor deck43 slidesOctober 2024
All 30 decks
DeckKindSlidesDate
Investor Presentation (September 2024)Investor deck37 slidesSeptember 2024
Investor Presentation (May 2024)Investor deck34 slidesMay 2024
Investor Presentation (April 2024)Investor deck34 slidesApril 2024
Investor Presentation (April 2024)Investor deck33 slidesApril 2024
Investor Presentation (January 2024)Investor deck33 slidesJanuary 2024
Investor Presentation (November 2023)Investor deck60 slidesNovember 2023
Investor Presentation (September 2023)Investor deck61 slidesSeptember 2023
Investor Presentation (June 2023)Investor deck59 slidesJune 2023
Investor Presentation (June 2017)Investor deck29 slidesJune 2017
Investor Presentation (September 2016)Investor deck31 slidesSeptember 2016
Investor Presentation (August 2016)Investor deck26 slidesAugust 2016
Investor Presentation (December 2015)Investor deck31 slidesDec 7, 2015
Investor Presentation (September 2015)Investor deck35 slidesSeptember 2015
Investor Presentation (September 2015)Investor deck35 slidesSeptember 2015
35th Annual Canaccord Genuity Growth Conference 2015Conference36 slidesAug 13, 2015
Investor Presentation (February 2015)Investor deck26 slidesFeb 18, 2015
Corporate Update (December 2012)Corporate update4 slidesDec 13, 2012
Investor Presentation (December 2011)Investor deck13 slidesDecember 2011
Investor Presentation (September 2011)Investor deck15 slidesSeptember 2011
Investor Presentation (November 2010)Investor deck18 slidesNov 10, 2010

Open Decks

Financings

RaiseDate
Common shares under equity line of credit (share purchase agreement)
Cancelled: raise
Buyers: Alumni (obligated to purchase up to US$20 million worth of common stock over a 15-month period); Alumni Capital
Use of proceeds: Funding to progress pelareorep's clinical development toward key clinical milestones
Aug 8, 2025
At-the-market programme of common shares
Cancelled: Cantor Fitzgerald
Dealers: Cantor Fitzgerald
Aug 8, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue000000000
Cost of revenue70.0K298.6K301.1K360.6K332.7K485.6K95.4K90.8K162.2K
Gross profit-70.0K-298.6K-301.1K-360.6K-332.7K-485.6K-95.4K-90.8K-162.2K
Research and development13.3M15.4M13.3M11.4M12.9M12.9M10.8M9.42M9.39M9.77M
Selling, general and administrative15.4M11.8M8.18M12.9M12.5M9.56M7.24M6.21M5.36M
Operating income-28.7M-25.5M-25.5M-19.8M-26.2M-25.5M-20.1M-16.7M-15.6M-15.3M
Depreciation and amortization70.0K87.0K303.8K288.8K452.0K446.0K485.6K95.4K90.8K162.2K
EBITDA-28.7M-25.5M-25.2M-19.5M-25.8M-25.0M-19.7M-16.6M-15.5M-15.1M
Interest expense528.0K138.4K00000
Income before tax-28.7M-22.7M-20.8M-18.2M-26.3M-22.5M-33.1M-16.5M-15.5M-15.1M
Income tax79.0K95.0K73.1K61.9K49.0K-2.95M12.4M548.0K141.5K9.37K
Net income-28.8M-22.8M-20.9M-18.3M-26.3M-22.5M-45.6M-17.0M-15.6M-15.1M
Earnings per share, basic-0.30-0.30-0.31-0.32-0.49-0.56-2.06-1.06-1.12-1.20
Earnings per share, diluted-0.30-0.30

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents5.20M11.1M34.9M11.7M41.3M31.2M14.1M13.7M11.8M12.0M
Short-term investments3.38M20.5M1.36M30.4M13.1M002.09M
Receivables786.2K15.0K521.0K866.0K89.7K2.07M51.6K4.80M54.4K
Inventory000
Current assets6.84M12.4M38.2M35.7M44.9M33.7M18.9M14.5M17.8M14.4M
Property, plant and equipment228.0K286.0K652.0K976.3K609.1K727.5K412.7K333.4K320.0K
Goodwill000
Total assets7.58M13.4M38.8M37.3M45.9M34.3M19.7M14.9M18.2M14.8M
Accounts payable3.50M756.0K1.08M2.25M594.0K1.81M3.17K1.83M3.68M4.07M
Current liabilities6.10M4.88M4.24M3.94M2.69M2.71M12.9M2.81M5.23M4.07M
Long-term debt000
Total debt772.5K423.0K373.0K655.0K402.1K506.3K
Total liabilities11.4M10.1M11.3M10.8M9.78M9.59M19.8M8.67M9.87M4.07M
Shareholders' equity-3.80M3.30M27.6M26.5M36.1M24.8M-107.9K6.20M8.28M10.7M
Shares outstanding108.0M80.0M67.6M58.0M53.5M40.3M22.1M16.0M13.9M12.6M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-20.1M-19.9M-21.4M-17.2M-22.4M-22.1M-19.9M-11.9M-14.9M-12.5M
Capital spending-6.00K-174.0K-6.03K-40.5K-286.0K-29.0K-10.9K-107.5K-105.8K-23.5K
Free cash flow-20.1M-20.1M-21.5M-17.2M-22.7M-22.1M-19.9M-12.0M-15.0M-12.5M
Cash from investing-6.00K-174.0K15.2M-15.0M-286.0K-29.0K-10.9K-107.5K1.98M-51.4K
Cash from financing14.1M5.03M24.1M8.99M33.0M39.8M21.0M13.3M12.8M956.1K
Dividends paid000
Share buybacks13.3M12.8M6.18K302
Change in cash-5.88M-15.3M17.5M-21.8M10.0M17.1M448.1K1.86M-198.2K-12.0M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 20, 2026Meeting outcomeSEC
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026Current reportSEC
8-K · Current reportNov 9, 2026Current reportSEC
8-K · Current reportNov 4, 2026Current reportSEC
8-K · Current reportOct 27, 2026Current reportSEC
8-K · Current reportOct 20, 2026Current reportSEC
8-K · Current reportOct 14, 2026Current reportSEC
8-K · Current reportOct 13, 2026Current reportSEC
DEFA14A · Additional proxy materialOct 6, 2026Meeting noticeSEC
Show 200 filings
FilingDateTypeFiled with
DEF 14A · Proxy statementOct 6, 2026Meeting noticeSEC
8-K · Current reportSep 29, 2026Current reportSEC
8-K · Current reportSep 28, 2026Current reportSEC
8-K · Current reportSep 10, 2026Current reportSEC
8-K · Current reportAug 18, 2026Current reportSEC
10-Q · Quarterly reportAug 12, 2026Quarterly reportSEC
8-K · Current reportJul 24, 2026Current reportSEC
8-K · Current reportJul 20, 2026Current reportSEC
8-K · Current reportJul 13, 2026Current reportSEC
8-K · Current reportJul 8, 2026Current reportSEC
8-K · Current reportJun 16, 2026Current reportSEC
3 · Initial statement of ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
8-K · Current reportJun 2, 2026Management or board changeSEC
8-K · Current reportJun 1, 2026Current reportSEC
8-K · Current reportMay 22, 2026Current reportSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 4, 2026Current reportSEC
8-K · Current reportApr 27, 2026Current reportSEC
F-10POSApr 8, 2026Other filingsSEC
F-10POSApr 8, 2026Other filingsSEC
F-10POSApr 8, 2026Other filingsSEC
F-10POSApr 8, 2026Other filingsSEC
F-10POSApr 8, 2026Other filingsSEC
F-10POSApr 8, 2026Other filingsSEC
F-10POSApr 8, 2026Other filingsSEC
F-10POSApr 8, 2026Other filingsSEC
F-10POSApr 8, 2026Other filingsSEC
F-10POSApr 8, 2026Other filingsSEC
AWApr 8, 2026Other filingsSEC
AWApr 8, 2026Other filingsSEC
AWApr 8, 2026Other filingsSEC
AWApr 8, 2026Other filingsSEC
AWApr 8, 2026Other filingsSEC
AWApr 8, 2026Other filingsSEC
AWApr 8, 2026Other filingsSEC
AWApr 8, 2026Other filingsSEC
AWApr 8, 2026Other filingsSEC
AWApr 8, 2026Other filingsSEC
F-10POSApr 6, 2026Other filingsSEC
F-10POSApr 6, 2026Other filingsSEC
F-10POSApr 6, 2026Other filingsSEC
F-10POSApr 6, 2026Other filingsSEC
F-10POSApr 6, 2026Other filingsSEC
F-10POSApr 6, 2026Other filingsSEC
F-10POSApr 6, 2026Other filingsSEC
F-10POSApr 6, 2026Other filingsSEC
F-10POSApr 6, 2026Other filingsSEC
F-10POSApr 6, 2026Other filingsSEC
8-K · Current reportApr 6, 2026Current reportSEC
424B5 · ProspectusApr 6, 2026Offer documentSEC
8-K · Current reportApr 6, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveApr 6, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 2, 2026Other filingsSEC
CORRESP · Letter to the SECApr 1, 2026Other filingsSEC
UPLOAD · Letter from the SECApr 1, 2026Other filingsSEC
8-K · Current reportApr 1, 2026Material contractSEC
F-10POSMar 31, 2026Other filingsSEC
F-10POSMar 31, 2026Other filingsSEC
F-10POSMar 31, 2026Other filingsSEC
F-10POSMar 31, 2026Other filingsSEC
F-10POSMar 31, 2026Other filingsSEC
F-10POSMar 31, 2026Other filingsSEC
F-10POSMar 31, 2026Other filingsSEC
F-10POSMar 31, 2026Other filingsSEC
F-10POSMar 31, 2026Other filingsSEC
F-10POSMar 31, 2026Other filingsSEC
S-8 POSMar 31, 2026Offer documentSEC
S-8 POSMar 31, 2026Offer documentSEC
POS AM · Amendment to an effective registrationMar 31, 2026Offer documentSEC
S-3 · Registration statementMar 31, 2026Offer documentSEC
S-8 · Registration statement for employee plansMar 31, 2026Offer documentSEC
10-K · Annual reportMar 30, 2026Annual reportSEC
8-K · Current reportMar 20, 2026Current reportSEC
8-K · Current reportMar 19, 2026Current reportSEC
4 · Change in ownershipMar 13, 2026Insider tradeSEC
4 · Change in ownershipMar 13, 2026Insider tradeSEC
8-K · Current reportMar 2, 2026Current reportSEC
8-K · Current reportFeb 24, 2026Current reportSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
8-K · Current reportFeb 4, 2026Current reportSEC
4 · Change in ownershipJan 20, 2026Insider tradeSEC
8-K · Current reportJan 15, 2026Meeting outcomeSEC
8-K · Current reportJan 14, 2026Current reportSEC
8-K · Current reportJan 12, 2026Current reportSEC
425Jan 9, 2026Other filingsSEC
6-K · Report of a foreign issuerJan 7, 2026Current reportSEC
3 · Initial statement of ownershipJan 2, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2026Insider tradeSEC
6-K · Report of a foreign issuerDec 16, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveDec 10, 2025Other filingsSEC
6-K · Report of a foreign issuerDec 9, 2025Current reportSEC
424B3 · ProspectusDec 9, 2025Offer documentSEC
F-4/ADec 5, 2025Offer documentSEC
CORRESP · Letter to the SECDec 5, 2025Other filingsSEC
6-K · Report of a foreign issuerNov 20, 2025Current reportSEC
6-K · Report of a foreign issuerNov 19, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerNov 12, 2025Current reportSEC
6-K · Report of a foreign issuerNov 4, 2025Current reportSEC
6-K · Report of a foreign issuerOct 28, 2025Current reportSEC
6-K · Report of a foreign issuerOct 20, 2025Current reportSEC
6-K · Report of a foreign issuerOct 17, 2025Current reportSEC
F-4Oct 17, 2025Offer documentSEC
424B5 · ProspectusOct 17, 2025Offer documentSEC
6-K · Report of a foreign issuerOct 10, 2025Current reportSEC
6-K · Report of a foreign issuerSep 29, 2025Current reportSEC
6-K · Report of a foreign issuerSep 16, 2025Current reportSEC
6-K · Report of a foreign issuerSep 8, 2025Current reportSEC
6-K · Report of a foreign issuerSep 2, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveSep 2, 2025Other filingsSEC
6-K · Report of a foreign issuerAug 28, 2025Current reportSEC
CORRESP · Letter to the SECAug 27, 2025Other filingsSEC
UPLOAD · Letter from the SECAug 27, 2025Other filingsSEC
F-3 · Registration statementAug 22, 2025Offer documentSEC
6-K · Report of a foreign issuerAug 11, 2025Current reportSEC
6-K · Report of a foreign issuerAug 8, 2025Current reportSEC
6-K · Report of a foreign issuerAug 8, 2025Current reportSEC
6-K · Report of a foreign issuerAug 8, 2025Current reportSEC
6-K · Report of a foreign issuerAug 8, 2025Current reportSEC
6-K · Report of a foreign issuerAug 5, 2025Current reportSEC
6-K · Report of a foreign issuerJul 29, 2025Current reportSEC
6-K · Report of a foreign issuerJul 23, 2025Current reportSEC
6-K · Report of a foreign issuerJul 22, 2025Current reportSEC
6-K · Report of a foreign issuerJul 16, 2025Current reportSEC
6-K · Report of a foreign issuerJul 10, 2025Current reportSEC
6-K · Report of a foreign issuerJul 8, 2025Current reportSEC
6-K · Report of a foreign issuerJul 8, 2025Current reportSEC
6-K · Report of a foreign issuerJun 30, 2025Current reportSEC
6-K · Report of a foreign issuerJun 11, 2025Current reportSEC
6-K · Report of a foreign issuerMay 23, 2025Current reportSEC
6-K · Report of a foreign issuerMay 14, 2025Current reportSEC
6-K · Report of a foreign issuerMay 14, 2025Current reportSEC
6-K · Report of a foreign issuerMay 8, 2025Current reportSEC
6-K · Report of a foreign issuerApr 24, 2025Current reportSEC
6-K · Report of a foreign issuerApr 10, 2025Current reportSEC
6-K · Report of a foreign issuerApr 10, 2025Current reportSEC
SUPPLApr 10, 2025Other filingsSEC
6-K · Report of a foreign issuerApr 10, 2025Current reportSEC
20-F · Annual reportMar 7, 2025Annual reportSEC
6-K · Report of a foreign issuerMar 7, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 25, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 19, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 18, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerFeb 14, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 10, 2025Current reportSEC
6-K · Report of a foreign issuerJan 22, 2025Current reportSEC
6-K · Report of a foreign issuerJan 15, 2025Current reportSEC
6-K · Report of a foreign issuerDec 23, 2024Current reportSEC
6-K · Report of a foreign issuerDec 18, 2024Current reportSEC
6-K · Report of a foreign issuerDec 3, 2024Current reportSEC
6-K · Report of a foreign issuerNov 12, 2024Current reportSEC
6-K · Report of a foreign issuerNov 12, 2024Current reportSEC
6-K · Report of a foreign issuerNov 12, 2024Current reportSEC
6-K · Report of a foreign issuerOct 4, 2024Current reportSEC
6-K · Report of a foreign issuerSep 19, 2024Current reportSEC
6-K · Report of a foreign issuerSep 6, 2024Current reportSEC

This page holds 200 of 1,001 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Oncolytics Biotech Inc.’s releases · as of Nov 13, 2026

Common shares
136,140,469
Fully diluted
136,140,469

Fully diluted

LineSharesAs of
Common shares136,140,469Nov 13, 2026

Share count over time

CountShares
Nov 13, 2026136,140,469

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Seeds Investor LLC258K0.19%US$173KSep 30, 2026
International Assets Investment Management, LLC202K0.15%US$129KSep 30, 2026
XTX Topco Ltd192K0.14%US$128KSep 30, 2026
Goldman Sachs187K0.14%US$125KSep 30, 2026
Larson Financial Group LLC168K0.12%US$112KSep 30, 2026
Tocqueville Asset Management L.P.157K0.12%US$105KSep 30, 2026
PFG Investments, LLC145K0.11%US$96,727Sep 30, 2026
Everhart Financial Group, Inc.142K0.10%US$95,112Sep 30, 2026
Invesco142K0.10%US$95,046Sep 30, 2026
Citigroup Inc121K0.09%US$81,161Sep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Doliver Advisors, LP100K0.07%US$66,820Sep 30, 2026
Fifth Third Bancorp85,5260.06%US$57,148Sep 30, 2026
Franklin Templeton79,8420.06%US$33,917Sep 30, 2026
LPL Financial LLC74,7460.05%US$49,945Sep 30, 2026
CIBC69,3030.05%US$46,308Sep 30, 2026
RBC58,8590.04%US$39,000Sep 30, 2026
BMO53,5890.04%US$35,809Sep 30, 2026
Catalyst Funds Management Pty Ltd51,6590.04%US$34,519Sep 30, 2026
Headinvest, LLC44,7000.03%US$29,869Sep 30, 2026
Badgley Phelps Wealth Managers, LLC40,0000.03%US$26,728Sep 30, 2026
Raymond James Financial Inc39,5860.03%US$26,451Sep 30, 2026
Clearstead Advisors, LLC39,0000.03%US$26,060Sep 30, 2026
Hrt Financial LP37,3320.03%US$24,000Sep 30, 2026
Federation des caisses Desjardins du Quebec36,4990.03%US$24,380Sep 30, 2026
Commonwealth Equity Services, LLC35,1140.03%US$23,460Sep 30, 2026
Professional Advisory Services Inc30,0000.02%US$20,000Sep 30, 2026
Vantage Point Financial LLC29,7440.02%US$19,875Sep 30, 2026
R Squared Ltd27,4110.02%US$18,316Sep 30, 2026
Citadel25,5170.02%US$17,051Sep 30, 2026
Bank of America25,0000.02%US$16,700Sep 30, 2026
StoneX Group Inc.24,3970.02%US$20,450Sep 30, 2026
Osaic Holdings, Inc.22,3000.02%US$14,941Sep 30, 2026
Morgan Stanley21,4470.02%US$14,330Sep 30, 2026
Stonebridge Financial Group, LLC21,0610.02%US$14,000Sep 30, 2026
Truist Financial Corp20,0000.01%US$13,364Sep 30, 2026
UBS16,5240.01%US$11,038Sep 30, 2026
PNC Financial Services Group, Inc.15,0550.01%US$10,057Sep 30, 2026
D.A. Davidson & Co.14,8250.01%US$9,906Sep 30, 2026
Ball & Co Wealth Management Inc.14,8230.01%US$9,905Sep 30, 2026
Victory Capital14,3210.01%US$9,569Sep 30, 2026
Blair William & Co13,201<0.01%US$8,821Sep 30, 2026
Creative Planning13,000<0.01%US$8,687Sep 30, 2026
Manhattan West Asset Management, LLC13,000<0.01%US$8,687Sep 30, 2026
AlphaCore Capital LLC12,500<0.01%US$8,353Sep 30, 2026
Ausdal Financial Partners, Inc.12,000<0.01%US$8,018Sep 30, 2026
Kingsview Wealth Management, LLC11,210<0.01%US$7,491Sep 30, 2026
Two Sigma11,123<0.01%US$7,432Sep 30, 2026
Stirlingshire Investments, Inc.11,000<0.01%US$7,350Sep 30, 2026
Rockefeller Capital Management L.P.10,939<0.01%US$7,309Sep 30, 2026
Cambridge Investment Research Advisors, Inc.10,771<0.01%US$7,000Sep 30, 2026

This page holds 50 of 77 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Fidelity Nasdaq Composite Index Fund66,9390.05%US$69,617May 31, 2026
Victory Extended Market Index Fund13,506<0.01%US$10,174Jul 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Patricia S Andrews
Other companies: Geron Corporation (Director · Since at least Mar 25, 2026); Crescent Biopharma, Inc. (Director · Jun 9, 2017 – May 1, 2024 · Past); Incyte Corporation (Chief Commercial Officer · Oct 21, 2008 – Jan 19, 2012 · Past)
Director · Since at least Jan 1, 2026
Bernd R. Seizinger
Other companies: Aprea Therapeutics, Inc. (Director · Since at least Oct 2, 2019); Aptose Biosciences Inc (Director · Sep 13, 2022 – Feb 5, 2024 · Past)
Director · Since at least Jan 1, 2026
James Parsons
Other companies: DiaMedica Therapeutics Inc. (Chairman of the Board · Since at least Dec 6, 2018); Trillium Therapeutics Inc (Chief Financial Officer · Jan 1, 2021 – Nov 17, 2021 · Past)
Director · Since at least Jan 1, 2026
Jonathan Rigby
Other companies: BioPlus Acquisition Corp (Chief Business Officer, Director · Dec 2, 2021 – Dec 2, 2021 · Past); SteadyMed Ltd (President and CEO, Director · Dec 28, 2017 – Aug 30, 2018 · Past)
Director · Since at least Jan 1, 2026
Wayne Pisano
Other companies: Altimmune, Inc. (Director · Since at least Aug 30, 2018); Provention Bio Inc (Director · Jul 3, 2018 – Apr 27, 2023 · Past)
Director · Since at least Jun 26, 2025
Andrew Aromando
Other companies: Ambrx Biopharma Inc. (Chief Operating Officer · Apr 28, 2023 – Mar 7, 2024 · Past)
Chief Business Officer · Since at least Jun 30, 2025
John McAdory
Other companies: CG Oncology, Inc. (EVP of Strategy and Operations · Jan 14, 2026 – Nov 5, 2026 · Past)
Chief Operating Officer · Since at least Jun 1, 2026
Allison HagermanChief Technology Officer · Since at least Nov 5, 2026
Angela HolthamDirector · Since at least Nov 4, 2026
Deborah M. BrownDirector · Since at least Jan 1, 2026
All 16 people
PersonSeat
Jared KellyChief Executive Officer & Director · Since at least Oct 27, 2026
Jon PattonDirector of Investor Relations & Communication · Since at least Oct 27, 2026
Kirk LookChief Financial Officer · Since at least Nov 5, 2026
Pat AndrewsDirector · Since at least Nov 5, 2026
Steve GloverDirector · Since at least Jun 2, 2026
Thomas C. HeinemanChief Medical Officer · Since at least Jan 1, 2026

Open People

Log in to ask 6ix AI your own questions about Oncolytics Biotech Inc.